These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581 [TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Sustainability of Using Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454 [TBL] [Abstract][Full Text] [Related]
5. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. AlMukdad S; Elewa H; Al-Badriyeh D J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168 [TBL] [Abstract][Full Text] [Related]
6. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention. Mohammad AM; Al-Allawi NAS J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005 [TBL] [Abstract][Full Text] [Related]
7. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
8. Advances in the Pharmacogenomics of Antiplatelet Therapy. Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157 [TBL] [Abstract][Full Text] [Related]
9. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Klein MD; Lee CR; Stouffer GA Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231 [TBL] [Abstract][Full Text] [Related]
11. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF; Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096 [TBL] [Abstract][Full Text] [Related]
13. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309 [TBL] [Abstract][Full Text] [Related]
18. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215 [TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Klein MD; Williams AK; Lee CR; Stouffer GA Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018 [TBL] [Abstract][Full Text] [Related]
20. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201 [No Abstract] [Full Text] [Related] [Next] [New Search]